Physician profile
Robert Ayres
NPI 1609507789
$349.68
in general payments reported to CMS, 2019-2025
13 companies · $69.03 in 2025
The $69.03 reported for 2025 was less than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $52.78 · 2024: $228 · 2025: $69.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $349.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $61.24 | 2024 | Xarelto |
| Gilead Sciences, INC. | $45.09 | 2023-2024 | Epclusa |
| Abbvie INC. | $38.78 | 2024 | |
| Lilly USA, LLC | $32.62 | 2024-2025 | Jardiance, Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $26.67 | 2023-2024 | Recarbrio, Zerbaxa, Dificid |
| Alexion Pharmaceuticals, INC. | $22.15 | 2025 | Koselugo |
| Astrazeneca Pharmaceuticals LP | $20.35 | 2024 | |
| Eisai INC. | $19.69 | 2024 | |
| Phathom Pharmaceuticals, INC. | $19.22 | 2024 | Voquezna |
| Novo Nordisk INC | $17.71 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $17.30 | 2023 | Inpefa |
| Amgen INC. | $15.36 | 2024 | Repatha |
| Otsuka America Pharmaceutical, INC. | $13.50 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ayres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.